These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 37555492)

  • 1. Improving the efficiency of clinical trials in multiple sclerosis.
    Marrie RA; Sormani MP; Apap Mangion S; Bovis F; Cheung WY; Cutter GR; Feys P; Hill MD; Koch MW; McCreary M; Mowry EM; Park JJ; Piehl F; Salter A; Chataway J
    Mult Scler; 2023 Aug; 29(9):1136-1148. PubMed ID: 37555492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
    Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
    Foo EC; Russell M; Lily O; Ford HL
    Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocrelizumab for the treatment of multiple sclerosis.
    Bigaut K; De Seze J; Collongues N
    Expert Rev Neurother; 2019 Feb; 19(2):97-108. PubMed ID: 30570368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of multiple sclerosis: current trials and future options.
    Noseworthy JH
    Curr Opin Neurol; 2003 Jun; 16(3):289-97. PubMed ID: 12858064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple sclerosis by phenotype in Germany.
    Engelhard J; Oleske DM; Schmitting S; Wells KE; Talapala S; Barbato LM
    Mult Scler Relat Disord; 2022 Jan; 57():103326. PubMed ID: 35158442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of trial design and patient heterogeneity on the identification of clinically effective therapies for progressive MS.
    Mills EA; Begay JA; Fisher C; Mao-Draayer Y
    Mult Scler; 2018 Dec; 24(14):1795-1807. PubMed ID: 30303445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel therapeutic options for multiple sclerosis.
    Curtin F; Hartung HP
    Expert Rev Clin Pharmacol; 2014 Jan; 7(1):91-104. PubMed ID: 24325127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitoxantrone for multiple sclerosis.
    Martinelli Boneschi F; Vacchi L; Rovaris M; Capra R; Comi G
    Cochrane Database Syst Rev; 2013 May; (5):CD002127. PubMed ID: 23728638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of anxiety symptoms and correlates of anxiety in people with progressive and relapsing-remitting multiple sclerosis.
    Knowles LM; Tingey JL; Newman AK; von Geldern G; Alschuler KN
    Mult Scler Relat Disord; 2022 Jul; 63():103918. PubMed ID: 35700673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges.
    Chataway J; Williams T; Li V; Marrie RA; Ontaneda D; Fox RJ
    Lancet Neurol; 2024 Mar; 23(3):277-301. PubMed ID: 38365380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of definitions for conversion to secondary progressive MS in a Danish nationwide population.
    Kopp TI; Bramow S; Illes Z; Kant M; Kristensen C; Rasmussen PV; Sellebjerg F; Magyari M
    Mult Scler Relat Disord; 2021 Nov; 56():103319. PubMed ID: 34666241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
    Rivera VM; Jeffery DR; Weinstock-Guttman B; Bock D; Dangond F
    BMC Neurol; 2013 Jul; 13():80. PubMed ID: 23841877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
    Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
    Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis.
    Chataway J; Nicholas R; Todd S; Miller DH; Parsons N; Valdés-Márquez E; Stallard N; Friede T
    Mult Scler; 2011 Jan; 17(1):81-8. PubMed ID: 20798135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.